These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 24516018

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T.
    J Clin Oncol; 2006 Jun 20; 24(18):2715-22. PubMed ID: 16782911
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Gliosarcoma arising from oligodendroglioma, IDH mutant and 1p/19q codeleted.
    Yasuda T, Nitta M, Komori T, Kobayashi T, Masui K, Maruyama T, Sawada T, Muragaki Y, Kawamata T.
    Neuropathology; 2018 Feb 20; 38(1):41-46. PubMed ID: 28812310
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
    Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, du Plessis DG, Warnke PC.
    Neurology; 2006 Jun 13; 66(11):1661-7. PubMed ID: 16769937
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. IDH-mutated astrocytomas with 19q-loss constitute a subgroup that confers better prognosis.
    Otani R, Uzuka T, Higuchi F, Matsuda H, Nomura M, Tanaka S, Mukasa A, Ichimura K, Kim P, Ueki K.
    Cancer Sci; 2018 Jul 13; 109(7):2327-2335. PubMed ID: 29752851
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Current Considerations in the Treatment of Grade 3 Gliomas.
    Jo J, Schiff D.
    Curr Treat Options Oncol; 2022 Sep 13; 23(9):1219-1232. PubMed ID: 35913658
    [Abstract] [Full Text] [Related]

  • 37. Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation.
    Khurana R, Rath S, Singh HB, Rastogi M, Nanda SS, Chauhan A, Kaif M, Hussain N.
    Asian Pac J Cancer Prev; 2020 Mar 01; 21(3):755-760. PubMed ID: 32212804
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Chemotherapy and radiotherapy combination extends survival for patients with oligodendroglial tumors.
    Printz C.
    Cancer; 2012 Sep 15; 118(18):4368. PubMed ID: 22952029
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.